Selected Open Clinical Trials

For inquiries, visit foxchase.org/ClinicalTrialsProgram or call 888-369-2427.

Gastrointestinal Cancer (Colorectal)

An Open-Label Expanded Access Study of TAS-102 In Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy
Steven J. Cohen, MD
14-067

Gastrointestinal Cancer (Gastroesophageal)

MM-111-13-02-04: Randomized, Open Label, Phase II Study of MM-111 and Paclitaxel With or Without Trastuzumab In Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroespohageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Crystal S. Denlinger, MD
13-001

Gastrointestinal Cancer (Hepatocellular)

54F28-004: A Phase Ib Dose Escalation Study of OMP-54F28 In Combination with Sorafenib In Patients with Hepatocellular Cancer
Crystal S. Denlinger, MD
13-053

Genitourinary Cancer (Renal)

AGS-003-007: ADAPT An International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma
David Y.T. Chen, MD, FACS
PARGOS001/12-058

A Phase III, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Elizabeth R. Plimack, MD
CA209214/14-043

Head and Neck Cancers

ECOG 3311: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-Dose IMRT in Resectable p16 + Locally Advanced Oropharynx Cancer
Miriam N. Lango, MD
ECOG3311/13-203

FER-HN-027: Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, with Correlative Studies in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01316757)
Ranee Mehra, MD
FERHN027/10-026

Hematologic Cancer (Lymphoma)

Phase I Dose Finding Study of Belinostat plus Cyclophosphamide/Vincristine/
Doxorubicin/Prednisone (BelCHOP) Regimen for Treatment of Patients with Peripheral T-cell Lymphoma
Stefan Barta, MD, MS, MRCP
14-026

A Randomized, Open-Label, Phase III Trial of Adcetris (Brentuximab Vedotin) +AVD Versus ABVD as Frontline Therapy In Patients with Advanced Classical Hodgkin Lymphoma
Nadia Khan, MD
14-022

Radiation

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Penny R. Anderson, MD
14-705/NSABPB51/RTOG 1304 

OER-RT-042: Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered with 3DCRT/IMRT for Palliation of Recurrent Tumors
C-M Charlie Ma, PhD
11044

Sarcoma

OER-SAR-043: Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (IND 112423) (NCT01462630)
Margaret von Mehren, MD
OERSAR043/11-042

Surgical

CALGB 70807: The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Marc C. Smaldone, MD, MSHP
CTSU70807

A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Elective Major Cancer Surgery
Nestor F. Esnaola, MD, MPH, MBA
14-036/SURG-073

Thoracic Cancer (Non-Small Cell Lung)

An Open-Label, Randomized, Phase III Trial of Nivolumab versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Hossein Borghaei, DO
CA209026

A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Hossein Borghaei, DO
C14018

A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination with Erlotinib In Patients with Recurrent or Metastatic Non-Small Cell Lung Cancer (IND 111879) (NCT01471964)
Hossein Borghaei, DO
FERTH036